BRAF and neoplasm: For example, exploring the association and interactions between primary tumour side [13], BRAF V600E mutation, and MMR deficiency, all of which individually are prognostic and predictive factors [14], or novel biomarker associations between RAS mutations and lung metastases [15] or tumour stage impacting sites of recurrence [16] all demonstrate how the comprehensive registry data set provides information not captured in a clinical trial data set.